
Traws Pharma Receives FDA Feedback on Flu Drug Development
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) announced receipt of key guidance from the U.S. Food and Drug Administration (FDA) regarding the development of its investigational antiviral, tivoxavir marboxil …
Traws Pharma Receives FDA Feedback on Flu Drug Development Read More